Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | AGPAT2 | O15120 | 4/20 | 0.39 |
| ▸ | GFER | P55789 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22232474 | 1.00 | NPC1 (0.44) | NPC1CYP3A4RAB9ACYP1A2CYP2C19 | |
| SCHEMBL22232177 | 0.91 | GAA (0.53) | NPC1CYP3A4RAB9AMAPTGAA | |
| SCHEMBL29454181 | 0.91 | GAA (0.53) | NPC1CYP3A4RAB9AMAPTGAA | |
| SCHEMBL22231721 | 0.87 | BPTF (0.41) | NPC1RAB9AMAPTGAATDP1 | |
| SCHEMBL29454349 | 0.87 | BPTF (0.41) | NPC1RAB9AMAPTGAATDP1 | |
| SCHEMBL22231911 | 0.86 | GAA (0.50) | NPC1CYP3A4RAB9ACYP1A2CYP2C19 | |
| SCHEMBL29454250 | 0.86 | GAA (0.50) | NPC1CYP3A4RAB9ACYP1A2CYP2C19 | |
| SCHEMBL31723230 | 0.84 | RAPGEF4 (0.51) | MAPTGAATDP1APPGFER | |
| SCHEMBL22232357 | 0.84 | MAPT (0.53) | NPC1RAB9AMAPTGAATDP1 | |
| SCHEMBL22232610 | 0.84 | RAPGEF4 (0.51) | MAPTGAATDP1APPGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545639-B2 | 3-substituted phenylamidine compounds, preparation and use thereof | PI INDUSTRIES LTD. (IN) | 2026-02-10 | — | — | US | claimed |
| US-20220089523-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI INDUSTRIES LTD. (IN) | 2022-03-24 | — | — | US | claimed |
| US-12545639-B2 | 3-substituted phenylamidine compounds, preparation and use thereof | PI INDUSTRIES LTD. (IN) | 2026-02-10 | — | — | US | disclosed |
| EP-4647426-A2 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI Industries Ltd. (IN) | 2025-11-12 | — | — | EP | disclosed |
| US-20220089523-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI INDUSTRIES LTD. (IN) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089523-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | H1-3, PRMT7, PFAS | NPC1 3413/4885CYP3A4 412/4885RAB9A 1065/4885 |
| US-12545639-B2 | 3-substituted phenylamidine compounds, preparation and use thereof | CBR1, CBR3, HCCS | NPC1 312/4885CYP3A4 264/4885RAB9A 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.